

CLOCKWORK ORANGE



Fybogel Orange contains natural fibre
and can be trusted to relieve constipation quickly
and maintain regularity.¹

®

Ispaghula Husk **BP**
REGULAR AS CLOCKWORK

FYBOGEL PRESCRIBING INFORMATION Indications: Conditions requiring a high-fibre regimen. **Dosage and Administration:** (To be taken in water) Adults and children over 12: One sachet morning and evening. Children 6-12 years: Half to one level 5ml spoonful depending on age and size, morning and evening. Children under 6 years: To be taken only on medical advice. **Contra-indications, Warnings, etc.:** Fybogel is contra-indicated in cases of intestinal obstruction and colonic atony. Each sachet contains 3.5g Ispaghula husk BP. **Basic NHS Price:** At May '90 60 sachets £4.24. **Eire:** 60 sachets IR £4.92. **PL No.:** Fybogel 44/0041, Irish PA 27/2/1, Fybogel Orange 44/0068, Irish PA 27/2/2. **Reference:** 1. Data on file, 394 Patient Study, Reckitt and Colman Pharmaceuticals, 1988. Fybogel is a trade mark of Reckitt & Colman Products Ltd. Further information is available from Reckitt & Colman Pharmaceuticals, Hull HU8 7DS.



SOME THINGS APPEAR TO



1) Marshall BJ, et al. Lancet 1988; 2: 1437-1442. 2) Marshall BJ, Warren JR. Lancet 1984; 1: 1311-1315. 3) Goodwin CS. Lancet 1988; 2: 1467-1469. 4) Smith AC, et al. Gut 1988; 29: A711. 5) Rauws EAJ, Tytgat GJNJ. ISBN 90-9002938-9. Amsterdam 1989. 6) Lambert JR, et al. Gastroenterology 1987; 92: 1489. 7) Borody TJ, et al. Gastroenterology 1988; 94: 43 (abstract). 8) Coghlan JG, et al. Lancet 1987; 2: 1109-1111.

Prescribing information: Presentation Coated tablets and liquid (a chewable tablet is also available in some

countries). Each tablet (or 5 ml dose) contains 120 mg tri-potassium di-citrate bismuthate (calculated as Bi_2O_3).
Indications Gastric and duodenal ulcers. Dosage and administration Two tablets (or two 5 ml doses) twice daily, half an hour before breakfast and half an hour before the evening meal, or alternatively one tablet (or one 5 ml dose) four times a day half an hour before each of the three main meals and two hours before going to bed, for 28 days. If necessary a further month's treatment may be given. Maintenance therapy with De-Nol is not indicated, but treatment may be repeated after an interval of one month. Contra-indications, warnings, etc. De-Nol should not be administered to patients with renal disorders and, on theoretical grounds, is contra-indicated in pregnancy. Special precautions De-Nol may inhibit the efficacy of orally administered tetracyclines. Side-effects Blackening of the stool usually occurs; nausea and vomiting have been reported. Darkening of the tongue may occur with De-Nol

Gist-brocades

Gist-brocades Pharmaceuticals, Division of Royal
Gist-brocades NV, Delft, Holland

BE SLIGHTLY DIFFERENT

Take for example peptic ulcers. For years people were convinced that the pathophysiology was related to gastric acid; healing no longer seemed to be a major problem. The high rate of ulcer relapse however proved that in most cases it was only temporary healing and not a definite cure.¹⁾

Helicobacter pylori*: the other factor

In 1983 J.R. Warren and B.J. Marshall²⁾ discovered an important factor in the pathogenesis of peptic ulcers: *Helicobacter pylori*. Since their historic publication in *The Lancet* more and more proof has been produced, reflected in a continuous stream of publications on the connection between the presence of *H. pylori* in the gastric mucosa on one hand and histologically proven gastritis and peptic ulcers on the other. There is now no doubt of the association between chronic gastritis, ulcer relapse and *H. pylori*.³⁾

De-Nol®: the only ulcer healer that is active against *H. pylori*

De-Nol® is the only ulcer healer that is active against *H. pylori*. The relapse rates after treatment with De-Nol are much lower than those with acid-suppressant preparations.⁴⁾ Studies have shown that among patients in whom *H. pylori* was eradicated and who remained *H. pylori* negative in the year of follow-up, the relapse rate of peptic ulcers was only 0-10%.^{4, 5, 6, 7, 8)} The pathogenesis and cure of peptic ulcers therefore appear to be slightly different from what was assumed for years.

* formerly known as
Campylobacter pylori




liquid only. Overdosage: Overdosage has rarely been reported. Gastric lavage, with intestinal evacuation and if necessary supportive therapy, would be indicated. Package quantities: treatment pack of 112 tablets or 112 liquid. Basic NHS price: Tablets: £ 20.98. Liquid: £ 14.65. Product licence numbers: Tablets: 0166 0724. Liquid: 0166 5024. GMS prices: De-Noltab: IR £ 20.65. De-Nol: IR £ 16.37. Product authorization numbers: De-Noltab: 62 22 2. De-Nol: 62 24 1. Product licence authorization holder: Brocades Great Britain Ltd, Brocades France, West Byfleet, Surrey KT14 6RA. Telephone: 0932 415536.

Product information can be ordered from countries worldwide. Please consult your pharmacist. For further product specific country information, UK 8912.

Tri-potassium di-citrate bismuthate (internationally known as colloidal bismuth subcitrate)

PROGRESS

In The Control Of Pancreatic Insufficiency



creon[®] 
pancreatin

RIGHT ON TARGET – RIGHT FROM THE START

Prescribing Information – Presentation: Brown-yellow capsules containing enteric coated granules of pancreatin equivalent to: 9,000 BP units of amylase, 8,000 BP units of lipase, 210 BP units of protease. Available in packs of 100. Basic NHS price £13.33. **Indication:** Pancreatic exocrine insufficiency. **Dosage and administration:** Adults and children: Initially one or two capsules with meals, then adjust according to response. The capsules can be swallowed whole, or for ease of administration they may be opened and the granules taken with fluid or soft food, but without chewing. If the granules are mixed with food, it is important that they are taken immediately, otherwise dissolution of the enteric coating may result.

Contra-indications, Warnings, etc: Contra-indications: Substitution with pancreatic enzymes is contra-indicated in the early stages of acute pancreatitis. Warnings: Use in pregnancy: There is inadequate evidence of safety in use during pregnancy. The product is of porcine origin. Rarely cases of hyper-uricosuria and hyper-uricaemia have been reported with high doses of pancreatin. Overdosage could precipitate meconium ileus equivalent. Perianal irritation could occur, and, rarely, inflammation when large doses are used. **Product Licence Number:** 5727/0001. **Name and address of Licence Holder:** Kali Chemie Pharma GmbH, Postfach 220, D-3000, Hannover 1, West Germany.

duphar Further information is available from:
Duphar Laboratories Limited, Gaters Hill, West End, Southampton SO3 3JD. Tel: 0703 472281.

CRA4/PE1/1/89

Quite simply
A SUPERIOR CHOICE TO H₂-ANTAGONISTS¹⁻³
 in erosive oesophagitis

67%

healed on **LOSEC**
 20mg once daily¹
 in 4 weeks

31%

healed on ranitidine
 150mg bd¹
 in 4 weeks

The figures speak for themselves

ONCE DAILY



*Conventional starting courses of ranitidine or cimetidine in erosive reflux oesophagitis (March 1990)

n = 152¹

omeprazole-Astra

1. Sandmark S et al. Scand J Gastroenterol 1988; **23**: 625-32.


2. Zeitoun P et al. Lancet 1987; **II**: 621-2.

3. Bate CM et al. Gut 1989; **30**: A1493-4.

Abbreviated Prescribing Information

Presentation: Losec capsules containing 20mg omeprazole. **Indications:** Healing of erosive reflux oesophagitis. Symptom relief is rapid, and the majority of patients are healed after 4 weeks. **Dosage:** Adults (including elderly): 20mg Losec once daily, given for 4 weeks. For those patients not fully healed after the initial course, healing usually occurs during a further 4 weeks' treatment. Losec has also been used in a dose of 40mg once daily in patients with reflux oesophagitis refractory to other therapy. Healing usually occurred within 8 weeks. Long-term maintenance treatment with Losec is not recommended. **Children:** There is no experience of the use of Losec in children. **Impaired renal or hepatic function:** Adjustment is not required. Patients with severe liver disease should not require more than 20mg Losec daily. **Contra-indications, Warnings, etc:** No known contra-indications to the use of Losec. Where gastric ulcer is suspected, the possibility of malignancy should be excluded before treatment with Losec is instituted, as treatment may alleviate symptoms and delay diagnosis. Avoid in pregnancy unless there is no safer alternative. Breast feeding should be discontinued if the use of Losec is considered essential. Losec is well tolerated. Nausea, headache, diarrhoea, constipation and flatulence have been reported but are rare. Skin rashes have occurred in a few patients. These events have usually been mild and transient, and there has been no consistent relationship with treatment. Losec can delay the elimination of diazepam, phenytoin and warfarin. Monitoring of patients receiving warfarin or phenytoin is recommended and a reduction of warfarin or phenytoin dose may be necessary when omeprazole is added to treatment. No evidence of an interaction with theophylline, progesterone or antacids. **Animal Toxicology:** Gastric

EC Cell Hyperplasia and carcinoids, localised to the oesophageal mucosa, have been observed in life-long studies in rats. These changes have been related to sustained hypergastrinaemia. No treatment-related mucosal changes have been observed in patients treated continuously for periods up to 4 years. **Pharmaceutical Precautions:** Use within one month of opening. Replace cap firmly after use. Dispense in original containers. **Legal Category:** POM. **Package Quantities and Basic NHS Cost:** Bottles of 5 capsules, £3.49; Bottles of 28 capsules, £36.50. **Product Licence Number:** P 0017 0258. **Product Licence Holder:** Astra Pharmaceuticals Ltd, Home Park Estate, Kings Langley, Herts WD15 8JH.



ASTRA

For further information please contact
 Astra Pharmaceuticals Ltd
 Telephone: (0923) 266191

Losec is a registered trade mark

Help free the ulcerative colitis patient

**NEW
INDICATION**

ASACOL
mesalazine* (5-aminosalicylic acid)

**IN MILD TO MODERATE ACUTE
ULCERATIVE COLITIS**

Effective acute therapy¹
Effective maintenance therapy²
No sulphapyridine side effects

Prescribing Information: Presentation: 'Asacol' Tablets, PL 0002/0173, each containing 400 mg mesalazine (5-aminosalicylic acid) coated with a pH-dependent resin (Eudragit S) formulated to release the active ingredient in the terminal ileum and colon. 120 (6 blister packs of 20 tablets), £28.58. **Uses:** For the treatment of mild to moderate acute exacerbations of ulcerative colitis. For the maintenance of remission of ulcerative colitis. **Dosage and administration:** Adults: Acute disease: 6 tablets a day in divided doses, with concomitant corticosteroid therapy where clinically indicated. Maintenance therapy: 3 to 6 tablets a day in divided doses. Children: There is no dose recommendation. Elderly: Use with caution and only where renal function is normal. **Contra-indications:** A history of sensitivity to salicylates. Severe renal impairment

(GFR less than 20 ml/min). Children under 2 years of age. **Precautions:** Not recommended in patients with renal impairment. Caution in patients with a raised blood urea or proteinuria. Avoid during pregnancy. Do not give with lactulose or similar preparations which lower stool pH. **Adverse reactions:** Headache, nausea, abdominal pain, diarrhoea. Exacerbation of the symptoms of colitis. Rarely, reversible pancreatitis. **Legal category:** POM. 14.8.89.

References

1. Riley SA et al. Gut 1988;29:669-74.
2. Riley SA et al. Gastroenterology 1988;94:1383-9

* mesalazine is the British approved name of 5-aminosalicylic acid

SK&F

Smith Kline & French Laboratories Limited

A SMITHKLINE BECKMAN COMPANY, Welwyn Garden City, Hertfordshire AL7 1EY

© 1989 Smith Kline & French Laboratories Limited. Authorised User of the trade mark 'Asacol' in the UK

FAST WORKER



PEPCID[®] PM 40

(famotidine)

mg

ONE AT NIGHT CAN MAKE THEIR DAY

Abridged Product Information

Refer to Data Sheet before prescribing.

INDICATIONS Duodenal ulcer; prevention of relapses of duodenal ulceration; benign gastric ulcer; hypersecretory conditions such as Zollinger-Ellison syndrome.

DOSAGE In duodenal and benign gastric ulcer, 40 mg at night for four to eight weeks. For prevention of duodenal ulcer recurrence, 20 mg at night. Initiate antisecretory therapy of Zollinger-Ellison syndrome with 20 mg every six hours and adjust to individual response. The maximum dosage used for up to one year was 480 mg daily.

CONTRA-INDICATION Hypersensitivity.

PRECAUTIONS Exclude any likelihood of gastric carcinoma before using 'Pepcid' PM. Consider reducing the daily dose if creatinine clearance falls to or below 30 ml/min. 'Pepcid' PM is not recommended in pregnancy, nursing mothers or children.

SIDE EFFECTS Rarely, headache, dizziness, constipation, diarrhoea. Less frequently, dry mouth, nausea, vomiting, rash, abdominal discomfort, anorexia, fatigue.

BASIC NHS COST 20 mg tablets, £14.00 for 28-day calendar pack and £25.00 for bottles of 50.

40 mg tablets, £26.60 for 28-day calendar pack and £47.50 for bottles of 50.

Product Licence Numbers:

20 mg tablets, 0025/0215; 40 mg tablets, 0025/0216.

Issued December 1989

© denotes registered trademark of Merck & Co., Inc., Rahway, NJ, USA



Thomas Morson Pharmaceuticals
Division of Merck Sharp & Dohme Limited
Hertford Road, Hoddesdon, Herts, EN11 9BU



SPECIFICALLY DEVELOPED
FOR THE SUPPRESSION OF
NOCTURNAL ACID

Rapid relief for patients gripped by IBS

Colofac rapidly relieves the symptoms of Irritable Bowel Syndrome by a direct action on colonic smooth muscle.

Colofac eliminates spasm without the anti-cholinergic side effects that can prove troublesome to the patient.



colofac[®]

mebeverine

loosens the grip of IBS

Prescribing Information

Presentation: White, sugar-coated tablets each containing 135mg mebeverine hydrochloride. Available in packs of 100. Basic NHS price £8.35. Yellow, banana-flavoured sugar-free suspension containing mebeverine pamoate equivalent to 50mg mebeverine hydrochloride per 5ml. Available in bottles of 300ml. Basic NHS price £3.50.

Indications: 1. Irritable bowel syndrome. 2. Gastro-

intestinal spasm secondary to organic diseases.

Dosage and Administration: Tablets: Adults and children ten years and over: One tablet three times a day, preferably 20 minutes before meals. Suspension: Adults and children ten years and over: 15ml (150mg) three times a day, preferably 20 minutes before meals. **Contra-indications, warnings, etc:** Animal experiments have failed to show any terato-

genic effects. However, the usual precautions concerning the administration of any drug during pregnancy should be observed. **Product Licence Number:** Tablets: 0512/0044; Suspension: 0512/0061.

Further information is available on request to the Company. Duphar Laboratories Limited, Gaters Hill, West End, Southampton, SO3 3JD. Telephone: 0703 472281

duphar

C/Hosp Ad/1/88

**Now you
can heal
NSAID-associated
ulcers without
stopping anti-arthritic
treatment...**

Zantac
RANITIDINE


**A joint venture
undertaken with confidence**

PRESCRIBING INFORMATION: INDICATIONS: Duodenal ulcer, benign gastric ulcer, ulcers associated with non-steroidal anti-inflammatory drugs (NSAIDs), oesophageal reflux disease, severe oesophagitis, chronic episodic dyspepsia. **DOSAGE:** *Adults:* Duodenal ulceration and gastric ulceration: A single 300mg dose at bedtime or 150mg twice daily in the morning and evening for four weeks. Alternatively, in duodenal ulcers, 300mg in the morning and evening for four weeks to achieve optimal healing. Continued maintenance treatment of 150mg at bedtime is recommended for patients with a history of recurrent ulceration. Ulcers following non-steroidal anti-inflammatory drug therapy or associated with continued non-steroidal anti-inflammatory drugs: 150mg twice daily for up to eight weeks. Chronic episodic dyspepsia: 150mg twice daily for six weeks, investigate early relapsers and non-responders. Oesophageal reflux disease: 300mg at bedtime or 150mg twice daily for up to eight weeks. Severe oesophagitis: 300mg four times daily for up to eight weeks (see data sheet for full dosage instructions). **CONTRA-INDICATIONS:** Patients with known hypersensitivity to ranitidine. **PRECAUTIONS:** Exclude the possibility of malignancy in gastric ulcer before instituting therapy, especially in middle-aged patients with new or recently changed dyspeptic symptoms. Regular supervision of patients with peptic ulcer and on NSAID therapy is recommended especially if elderly. Reduce dosage in

the presence of severe renal failure (see data sheet). Like other drugs, use during pregnancy and lactation only if strictly necessary. **SIDE EFFECTS:** Headache, dizziness, skin rash, occasional hepatitis. Rarely, reversible mental confusion states, usually in very ill or elderly patients. Rare cases of leucopenia and thrombocytopenia, usually reversible, agranulocytosis and pancytopenia. Hypersensitivity reactions, anaphylactic shock. Rare cases of breast symptoms in men. As with other H₂-receptor antagonists rare cases of bradycardia, A-V block and asystole (see data sheet). **PRESENTATIONS:** Zantac 150 Tablets each containing 150mg ranitidine (Product Licence number 0004/0279, 60 tablets £29.76); Zantac 300 Tablets each containing 300mg ranitidine (Product Licence number 0004/0302, 30 tablets £27.43); Zantac Dispersible Tablets each containing 150mg ranitidine (Product Licence number 0004/0298, 60 tablets £31.25); Zantac Syrup each 10ml dose containing 150mg ranitidine (Product Licence number 0004/0310, 300ml bottle £22.32). **PRODUCT LICENCE HOLDER:** Glaxo Operations U.K. Limited, Greenford, Middlesex UB6 0HE. Zantac is a Glaxo trade mark. Further information is available on request from: Glaxo Laboratories Limited, Greenford, Middlesex UB6 0HE. Tel: 081-422 3434

Glaxo 

STRENGTH AGAINST REFLUX'



In the management of reflux oesophagitis and hiatus hernia the role of Liquid Gaviscon is well established. Liquid Gaviscon deals with reflux simply and physically by forming a neutral layer or 'raft' on gastric contents to inhibit reflux and so bring effective relief of reflux-related upper gastro-intestinal symptoms.

More recently an in-vitro comparison¹ using computer-based techniques, has shown that Liquid Gaviscon produces a 'raft' more resistant to upward pressures than any other alginate-containing compound tested.

Liquid Gaviscon[®]

Sodium Alginate BPC, Sodium Bicarbonate Ph.Eur.,
Calcium Carbonate Ph.Eur.

a logical choice in reflux

Prescribing Information

Active Ingredients: Sodium Alginate BPC 500mg, Sodium Bicarbonate Ph.Eur. 267mg, Calcium Carbonate Ph.Eur. 160mg per 10ml dose. **Indications:** Heartburn, including heartburn of pregnancy, dyspepsia associated with gastric reflux, hiatus hernia and reflux oesophagitis. **Contra-indications:** None known.

Dosage and Administration: Adults, children over 12: 10-20ml liquid after meals and at bedtime. Children under 12: 5-10ml liquid after meals and at bedtime. Infants: not recommended.

Note: 10ml liquid contains 6.2mmol sodium. **Basis NHS Cost:** As at Jan. 1989: 500ml liquid £2.88. **PL:** 44/0058.

Irish Price IR £3.72. **Irish P.A. No.:** 27/12/1.

Reference

1. Washington, N. *et al.*, *Int. J. Pharmaceut.* (1986) **28**, 139-143

Further information is available on request.
Reckitt & Colman Pharmaceutical Division,
Hull HU8 7DS.

*Registered trade mark.



THE QUALITIES OF LEADERSHIP



Experience

Unique among foam treatments, Colifoam has over 12 years of proven efficacy and safety in clinical practice.

Trust

Equally as effective as steroid enemas,^{1,2} Colifoam is well documented and is

the most prescribed topical treatment³ for ulcerative colitis.

Confidence

Colifoam's simplicity and effectiveness has transformed the lives of thousands of patients, enabling them to pursue active social and working lives.¹

COLIFOAM
10% Hydrocortisone acetate foam.

The leading topical treatment for ulcerative colitis.

PRESCRIBING INFORMATION: Presentation: White odourless aerosol containing hydrocortisone acetate PhEur 10%. Uses: Ulcerative colitis, proctosigmoiditis and granular proctitis. Dosage and administration: One applicatorful inserted into the rectum once or twice daily for two or three weeks and every second day thereafter. Shake can vigorously before use (illustrated instructions are enclosed with pack). Contra-indications, warnings etc.: Local contra-indications to the use of intrarectal steroids include obstruction, abscess, perforation, peritonitis, fresh intestinal anastomoses and extensive fistulae. General precautions common to all corticosteroid therapy should be observed during treatment with Colifoam. Treatment should be administered with caution in patients with severe ulcerative disease because of their predisposition to perforation of the bowel wall. Safety during pregnancy has not been fully established. Pharmaceutical precautions: Pressurized container. Protect from sunlight and do not expose to temperatures above 50°C. Do not pierce or burn even after use. Do not refrigerate. Keep out of reach of children. For external use only. Legal category: POM. Package Quantity & Basic NHS cost: 25g canister plus applicator, £7.25. Further Information: One applicatorful of Colifoam provides a dose of approximately 125mg of hydrocortisone acetate, similar to that used in a retention enema, for the treatment of ulcerative colitis, sigmoiditis and proctitis. Product Licence No.: 0036/0021. References 1. Somerville KW et al. British Medical Journal 1985; 291:866. 2. Ruddell WSJ et al. Gut 1980; 21:885-889. 3. Independent Research Audit. Data on File. Further information is available on request. Stafford-Miller Ltd., Professional Relations Division, Broadwater Road, Welwyn Garden City, Herts. AL7 3SP.

CYTOTEC

Abbreviated Prescribing Information

Presentation: Tablet containing misoprostol 200 micrograms.

Uses: Healing of duodenal and gastric ulcer induced by non-steroidal anti-inflammatory drugs (NSAID) in arthritic patients at risk, whilst continuing NSAID therapy. Prophylaxis of NSAID-induced ulcers. Healing of duodenal and gastric ulcer.

Dosage: Adults including the elderly. Healing of duodenal and gastric ulcer: 800 micrograms daily in two or four divided doses taken with breakfast and/or each main meal and at bedtime.

Prophylaxis of NSAID-induced ulcer:

200 micrograms twice daily, three times daily or four times daily. Refer to data sheet for additional information.

Contraindications: Pregnant women, women planning a pregnancy, patients allergic to prostaglandins.

Warnings: Pre-menopausal women should use effective contraception and be advised of the risks of taking Cytotec if pregnant.

Precautions: Cytotec does not produce hypotension in clinical studies at ulcer-healing doses, nevertheless exercise caution in disease states where hypotension might precipitate severe complications. Cytotec should not be administered during breast feeding.

Adverse effects: Diarrhoea, abdominal pain, dyspepsia, flatulence, nausea, vomiting, dizziness, skin rashes.

menstrual pain, menorrhagia,

epistaxis, nosebleeds.

Soften the impact of NSAIDs on the stomach with prostaglandins

Cytotec is a prostaglandin analogue and therefore replaces G.I. prostaglandins depleted by NSAIDs.

Unlike H₂ receptor antagonists, Cytotec not only inhibits gastric acid secretion¹ but also protects the gastric mucosa by stimulating bicarbonate secretion,² increasing mucus secretion¹ and enhancing gastric mucosal blood flow.³

1. Wilson DJ, Quadros L,

Rajapaksa T, Adams A, Noar M. Dig Dis Sci 1986; 31 (suppl): 126s-129s.

2. Isenberg JL, Hogan DL, Koss MA, Selling JA. Gastroenterology 1986; 91: 370-378.

3. Sato N, Kawano S, Fukuda M, Tsuji S, Kamada T. Am J Med 1987; 83 (suppl 1A): 15-21.

SEARLE
GOLD
CROSS

G.D. Searle & Co. Ltd.,
P.O. Box 53, Lane End Road,
High Wycombe, Bucks. HP12 4HL.
Cytotec, Gold Cross and Searle are
registered trademarks.

F March 1990

ONLY

CYTOTEC®

misoprostol





Dipentum[®]

olsalazine

in Ulcerative Colitis

Delivers
5-ASA
to the
colon...

... not to
the kidneys

Prescribing information

Presentation. Caramel coloured capsules containing 250mg olsalazine sodium.
Uses. Oral treatment of acute mild ulcerative colitis and the maintenance of remission. Olsalazine consists of two molecules of 5-amino-salicylic acid (5-ASA) joined through an azo-bond. The systemic absorption of olsalazine is minimal, 99% of an oral dose will reach the colon. Olsalazine is activated in the colon where it is converted into 5-ASA. The release of 5-ASA is neither pH nor time dependent. 5-ASA acts topically on the colonic mucosa and local colonic concentrations of 5-ASA

are more than 1000 times that found in the serum.
Dosage and Administration.
Acute Mild Disease. Adults *Including the Elderly.* Commence on 1g daily in divided doses and, depending upon the patient response, titrate the dose upwards to a maximum of 3g daily over 1 week. A single dose should not exceed 1g. Olsalazine should be taken with food.
Remission. Adults *Including the Elderly.* 2 capsules, 0.5g, twice daily taken with food.
Contra-Indications, Warnings, etc. *Contra-indications.* Hypersensitivity to salicylates. There is no experience of the use

of olsalazine in patients with significant renal impairment. Olsalazine is contra-indicated in patients with significant renal impairment.
Pregnancy. Comprehensive animal reproductive toxicity studies have not been performed. There is no experience with olsalazine treatment during pregnancy. Olsalazine is contra-indicated in pregnancy.
Lactation. There are no data on the excretion of olsalazine in breast milk.
Adverse Reactions. Watery diarrhoea has been recorded in 15% of patients treated. In half of these patients the diarrhoea was either transient or overcome by

dose reduction. In patients who do not respond to dose reduction the drug should be stopped. As with sulphasalazine and mesalazine gastrointestinal side-effects are the most common. The most frequently reported adverse reactions are diarrhoea, abdominal cramps, headache, nausea, dyspepsia, arthralgia and rash.
Treatment of Overdosage. There is no specific antidote to olsalazine. Treatment should be supportive.
Pharmaceutical Precautions. Store at room temperature in a dry place.
Legal Category. POM.

Package Quantities. Containers of 100 capsules.
Further Information. Olsalazine has been used concomitantly with glucocorticosteroids.
UK Product Licence Number. 0009/0069.
Product Authorisation Number (Ireland): PA 107/14-1.
Dipentum is a Trade Mark. Basic NHS Price: 100 Capsules £23.90.


Distributed in the Republic of Ireland by:
United Drug Limited,
7, Lower Fitzwilliam Street,
Dublin.

Further information available from:
Pharmacia Ltd.,
Pharmacia House,
Midsummer Boulevard,
Milton Keynes, MK9 3HP

 **Pharmacia**
Advancing The New Biology

PRESCRIBING INFORMATION

2. Premedication prior to general anaesthesia. 3. Control of acute muscle spasm due to tetanus or poisoning. 4. Control of convulsions; status epilepticus. 5. Management of severe anxiety states including delirium tremens. **DOSAGE AND ADMINISTRATION** Diazemuls may be administered by slow intravenous injection (1ml per min), or by continuous infusion. Diazemuls should be given as a bolus immediately prior to administration. 1. Sedation: 0.1 – 0.2mg diazepam/kg body weight by iv injection. 2. Premedication: 0.1 – 0.2mg diazepam/kg body weight by iv injection. 3. Tetanus: 0.1 – 0.3mg diazepam/kg body weight by iv injection repeated every 1-4 hours as required. Alternatively, continuous infusion of 3-10mg/kg body weight every 24 hours may be used. 4. Status epilepticus: An initial dose of 0.15 – 0.25mg/kg body weight by iv injection repeated in 30 to 60 minutes if required, and followed if necessary by infusion of up to 3mg/kg body weight over 24hr. 5. Anxiety and tension, acute muscle spasm, acute states of excitation, delirium tremens: The usual dose is 10mg repeated at intervals of 4 hours, or as required. Elderly or debilitated patients: Elderly and debilitated patients are particularly sensitive to benzodiazepines and should receive only half of the normal recommendations. **CONTRA-INDICATIONS, WARNINGS, ETC:** As with other benzodiazepine preparations, should not be used in phobic or obsessive compulsive states. Treatment with diazepam may cause drowsiness and increase the patient's reaction time. Use with caution in patients with impairment of renal or hepatic function, in patients with glaucoma, or myasthenia gravis. Should not be used alone to treat depression or anxiety associated with depression. Amnesia may occur. In cases of loss or bereavement psychological adjustment may be inhibited by benzodiazepines. Disinhibiting effects may be manifested in various ways. Suicide may be precipitated in patients who are depressed and aggressive behaviour toward self and others may be precipitated. Extreme caution should therefore be used in prescribing benzodiazepines in patients with personality disorders. Physiological and psychological symptoms of withdrawal including depression may be associated with discontinuation of benzodiazepines even after normal therapeutic doses for short periods of time. **Pregnancy and Lactation:** Diazepam crosses the placenta and should not be used during pregnancy unless considered essential. Large maternal doses administered during delivery may produce clinical effects in the newborn. Diazepam can be transmitted in breast milk and clinical effects may occur in the breast-fed infant. **Side Effects:** May rarely cause local pain or thrombophlebitis. Rare instances of a local painless erythematous rash around the site of injection. Urticaria and, rarely, anaphylaxis have been reported. **Overdosage:** CNS depression and coma. Treatment symptomatic. **PHARMACEUTICAL PRECAUTIONS:** See Data Sheet. **Pack Size & Cost:** 10 x 2ml ampoules: NHS Price £6.29. Product Licence No: 10183/0001. Date of preparation: June 1999 (Diazemuls is a registered trademark). Product Licence Holder: Dumex Ltd., Longwick Road, Princes Risborough, Buckinghamshire, Bucks HP17 9LZ. Tel: 0844 274414. Full prescribing information is available on request.




A gentle approach
to I.V. sedation

DUMEX

Diazemuls[®]
10mg diazepam in 2ml emulsion

PREDICTABLE I.V. SEDATION · PREDICTABLE RECOVERY



For hands-on experience of the new
High Performance 'X'-Range of Endoscopes
contact Pentax Medical Division

PENTAX
LOOKING AHEAD

Pentax UK Limited, Medical Division, Pentax House, South Hill Avenue,
South Harrow, Middlesex, HA2 0LT. Tel: 081-864 4422



NO MORE BROKEN

IRRITABLE BOWEL SYNDROME
COLPERMIN™
(enteric-coated peppermint oil) CAPSULES

Offers effective relief right where it hurts

Presentation: Each enteric-coated capsule contains 0.2ml peppermint oil Ph. Eur. **Uses:** Treatment of symptoms of irritable bowel syndrome. **Dosage and Administration:** Adult dose: 1-2 capsules three times a day, 30 minutes to one hour before food. Not to be taken immediately after food. The capsules should be taken until symptoms resolve, usually within one or two weeks. There is no experience of use in children under the age of 15 years. **Contra-indications, warnings, etc. Precautions:** Do not break or chew the capsules. Patients who already suffer from heartburn sometimes experience an exacerbation of these

symptoms when taking the capsule. Treatment should be discontinued in these patients. Do not take indigestion remedies at the same time of day as this treatment. **Adverse effects:** Heartburn; sensitivity reactions to menthol, which are rare and include erythematous skin rash, headache, bradycardia, muscle tremor and ataxia. **Pharmaceutical Precautions:** Store in a cool place. Avoid direct sunlight. **Legal category:** P. **Product Licence:** PL 0424/0009. **Basic NHS Cost:** £12.15 per 100. **Date of issue:** September 1989. Colpermin is a Trade Mark. 9168018-04-90

Tillotts Laboratories, Italia House, Grosvenor Road, St Albans, Hertfordshire AL1 3AW



PENTAX


IMAGES FOR THE FUTURE

The Pentax Video Endoscope System – compatible with conventional scopes.
For further details or to arrange a demonstration, contact Pentax U.K. Ltd., Medical Division,
Pentax House, South Hill Avenue, South Harrow, Middlesex, HA2 0LT. Tel: 081-864 4422

LOOKING AHEAD

Klean-Prep*

Polyethylene glycol 3350, sodium sulphate, sodium bicarbonate, sodium chloride, potassium chloride



Today's choice for a clean colon

for colonoscopy, colonic surgery, barium enema

- **Bowel cleansing**
Superior bowel cleansing to standard regimens^(1,2).
- **Safety**
Negligible water and electrolyte disturbance⁽³⁾.
- **Well tolerated**^(1,2,4)
Pleasantly flavoured.
- **Economy**
Shortens preoperative stay^(1,2,4).

Abbreviated Prescribing Information: **Presentation:** An off-white powder, packed in 4 sachets. Each sachet contains: Polyethylene Glycol 3350 59.00g, Sodium Sulphate 5.685g, Sodium Bicarbonate 1.685g, Sodium Chloride 1.465g, Potassium Chloride 0.7425g. **Uses:** Bowel preparation before colonoscopy, colonic surgery, radiological examination and other related procedures. **Dosage and Administration:** Reconstituted solution for oral administration. **Adults (including the elderly):** The contents of one sachet to be dissolved in 1 litre of water. 250ml to be drunk rapidly every 10-15 minutes until all the solution has been consumed. The procedure to be repeated with all four sachets or until the rectal effluent is clear. The solution from all 4 sachets should be drunk within 4-6 hours. No dosage changes need be made for patients with renal insufficiency. If administered by nasogastric tube the rate of administration should be 20-30ml/minute. **Children:** Not recommended. **Contra-indications, Warnings etc.** **Contra-indications:** Gastro-intestinal obstruction or perforation, ileus, gastric retention, acute intestinal or gastric ulceration, toxic colitis or megacolon. Patients with body weight less than 20kg. **Warnings:** Extra care should be taken in patients with impaired gag reflex, reflux oesophagitis, those with diminished levels of consciousness and in ulcerative colitis. **Interactions:** All oral medications should be given at least 1 hour prior to administration. **Side-effects:** Nausea, abdominal fullness, bloating may be experienced. Abdominal cramps, vomiting and anal irritation occur less frequently. These effects normally subside rapidly. Urticaria and allergic reactions have been reported rarely. Should distension or pain arise the rate of administration may be slowed. **Use in Pregnancy:** Careful consideration should be given before use in pregnancy. **Precautions:** The reconstituted solution should be refrigerated and used within 24 hours. Any unused portion should be discarded. **Package quantity:** Unit dose pack of 4 sachets. **Basic NHS price:** £8.60. PL 5628/0003 Licence holder: Birex Pharmaceuticals Ltd. Further information is available from Norgine Limited. *Klean-Prep is a trademark.

Distributed by NORGINE.




Norgine Limited
116-120 London Road
Oxford OX3 9BA

References 1 Fleites RA et al 1985 Surgery 98 4: 708-717; 2 Ernstoff JJ et al 1983 Gastroenterology 84: 1512-1516; 3 Davis GR et al 1980 Gastroenterology 78: 991-995; 4 Beck DE et al 1985 Southern Med J 78: 1414-146.

Picture © Telemed 1989

For further information on Klean-Prep, please return this coupon to:
Norgine Ltd, FREEPOST (OF 676), Oxford OX3 9BR

NAME _____
ADDRESS _____



no compromise

After a thorough development programme and extensive clinical trials, we now have available a non-invasive test for *Helicobacter pylori* – an organism implicated in duodenal ulcer and gastritis.

Based on a well characterised antigen, developed by scientists at the Centre for Applied Microbiology and Research, **HELICO-G™** is an enzyme immunoassay that will quantify IgG antibodies to *Helicobacter pylori*. 95% of patients diagnosed with *H pylori* were correctly identified by **HELICO-G™**, proving it to be a consistent, high quality assay.

Convenient, rapid, reliable results, backed up by extensive clinical trial data, give you greater confidence.




Why compromise?

HELICO – G™

**A SERO-DIAGNOSTIC KIT FOR
DETERMINATION OF ANTIBODIES TO
HELICOBACTER PYLORI IN HUMAN SERUM.**





Porton Cambridge Ltd, Porton House,
Vanwall Road, Maidenhead,
Berks SL6 4UB, United Kingdom.
Tel. 0628-771417. Fax 0628-770211.




In Ulcerative Colitis New Pentasa Slow Release Tablets

Predictable Release
in Unpredictable Conditions



- Predictable Release in Unpredictable Intestinal Transit^{1,2}
- Predictable Release in Unpredictable Intestinal pH²
- Predictable Release in Unpredictable Patients



Pentasa....Mesalazine, when and where it matters

Abridged Prescribing Information

Name of Product: PENTASA Slow Release Tablets. **Presentation:** Round, white to light grey mottled tablets with a break line on one side. Each tablet contains 250mg mesalazine in a slow release presentation. **Uses:** For the maintenance of remission in mild to moderate ulcerative colitis. **Dosage and administration:** Adults: The usual dose is two tablets, three times daily. **Contra-indications:** Children under the age of 15 years. Known sensitivity to salicylates. **Precautions, warnings etc:** PENTASA is not recommended in patients with renal impairment. Patients with raised blood urea or proteinuria should be treated with caution. PENTASA should be used with caution during pregnancy and lactation. Headache, diarrhoea and dyspepsia may occur in a small proportion of patients. Exacerbation of the symptoms of colitis may arise in patients who have previously had this problem with sulphasalazine. **Packing quantity:** Bottles containing 200 tablets. **Product Licence:** PL 3194/0043 Basic NHS **Price:** 200 x 250 mg tablets £32.28. **Product Licence Holder:** Ferring Pharmaceuticals Ltd, 11 Mount Road, Feltham, Middlesex, TW13 6JG. **Date of preparation:** March 1990. **Reference:** 1. Brit. J. Clin. Pharmac. (1987), 23: 365-369. 2. Gastroenterol. Int. (1988); 1/Suppl.1: A859. PENTASA is a registered trademark.

Further information is available from: Nordic Pharmaceuticals, 11 Mount Road, FELTHAM, Middlesex, TW13 6JG. **NORDIC** ☼

The
MEMOIR
Club

A selection of recent titles

Festina Lente—a Psychiatric Odyssey by Henry R Rollin
Henry Rollin insists that *Festina Lente* is "in no way an autobiography. I prefer to regard it essentially as a history during the past half century as seen by one who has been witness to and played some small part in the shaping of events." The book includes his analysis of the history and evolution of Horton Hospital; the dissolution of mental hospitals and the myth of community care; outpatient departments; and the development of different physical and psychopharmacological treatments. Psychiatry and the arts are combined in two chapters, "The therapeutic use of music in a mental hospital" and "Literary excursions," which examines the characters of Hamlet, Byron, George Bernard Shaw, and James Joyce. Appropriately, this psychiatric odyssey ends with the late arrival of true love.

Price: Inland £14.95; Abroad £17.50

BMA members: Inland £13.95; Abroad £16.50

Not a Proper Doctor

by David Sinclair
Sinclair was intent on a career in surgery when he graduated from St Andrew's University but fate, mainly in the shape of the second world war, decreed otherwise and he eventually became the first professor of anatomy at the University of Western Australia. As Professor Sinclair looks back on his varied life, there are moments of joy, sadness, and regret, but throughout a central core of humour and compassion—the stuff that "proper" doctors are made of.

Price: Inland £14.95; Abroad £18.50

BMA members: Inland £13.95; Abroad £17.50

Not a Moment to Lose

by Sir David Smithers
Sir David Smithers, former president of the British Institute of Radiology and of the Royal College of Radiologists, was for 30 years professor of radiotherapy at the Royal Marsden Hospital. But that is only half the story. He is also a man who believes "one should aspire to be a realist, but retain a sense of wonder, a rationalist who is prepared to jump to conclusions, and a critical visionary who remains sensible of the humour of the human situation".

Price: Inland £14.95; Abroad £17.50

BMA members: Inland £13.95; Abroad £16.50

One Man's Medicine by Archie Cochrane with Max Blythe
The autobiography of Professor Archie Cochrane, who was one of Britain's influential thinkers on health care and the quality of health services. His 30 years' association with the Rhondda Fach—and his work there on reducing the suffering inflicted on whole communities by pneumoconiosis—is almost legendary. Ironically, this was nearly overshadowed later in his life by the spectacular success of his Rock Carling monograph *Effectiveness and Efficiency*, which proved to be a seminal work and influenced thinking about the assessment of medical treatment and procedures throughout the world.

Price: Inland £14.95; Abroad £19.00

BMA members: Inland £13.95; Abroad £18.00

All prices include postage, by air abroad
Please enclose payment with order, or send us full details of your MASTERCARD, VISA or AMERICAN EXPRESS credit card.

BMJ

Available from:
BRITISH MEDICAL JOURNAL
PO Box 295, London WC1H 9TE
or your leading bookseller, or the BMJ/BMA
bookshop in BMA House.

TAGAMET

CIMETIDINE 800

*A literature search of clinical studies including at least 50 patients per treatment group showed that the mean 4-week healing rates for duodenal ulcers treated with a one tablet nocte healing regimen were similar for all the marketed H₂ antagonists¹⁻²⁰ †Prices derived from MIMS, October 1989, based on manufacturers' recommended 4-week one tablet nocte healing regimens.

References: 1. Bijlsma JWJ. *Aliment Pharmacol Therap* 1988;2S:75-83. 2. *ibid* 85-96. 3. Simon B *et al.* *J Clin Gastroenterol* 1986;8:367-70. 4. Lee FI *et al.* *Gut* 1986;27:1091-5. 5. Granata F. *Ital J Gastroenterol* 1985;7:208-10. 6. Brackmann HP *et al.* *Therapiewoche* 1984;34:5232-7. 7. Gibinski K *et al.* *Gastroenterol* 1985;88:1393. 8. Dobrilla G *et al.* *Scand J Gastroenterol* 1987;22 (Suppl 134):21-8. 9. Simon B *et al.* *Scand J Gastroenterol* 1987;22 (Suppl 136): 61-70. 10. Bovera E *et al.* *Hepato-gastroenterol* 1987;34: 269-72. 11. Marks IN, Wright JP. *S Afr Med J* 1987;72:18-20. 12. Rampal P *et al.* *Gastroenterol* 1988;94:A167. 13. Kogut DG *et al.* *Gastroenterol* 1988;94:A233. 14. Merki H *et al.* *Am J Gastroenterol* 1988;83:362-4. 15. Reynolds JC *Gastroenterol* 1988;94:A374. 16. Bianchi Porro G *et al.* *J Clin Gastroenterol* 1987;9 (Suppl 12):14-18. 17. Gitlin N *et al.* *Gastroenterol* 1987;92:48-53. 18. Mann SG, Cottrell J. *Ital J Gastroenterol* 1987;19 (Suppl 30):68. 19. Dyck WP *et al.* *Scand J Gastroenterol* 1987;22 (Suppl 136):47-55. 20. Delattre M *et al.* *Curr Ther Res* 1985;37:677-84.

Prescribing Information. Presentation 'Tagamet Tiltab' Tablets, PL 0002/0128, each containing 800 mg cimetidine. 30 (2 calendar strips of 15 tablets), £17.76. 'Tagamet' Tablets, PL 0002/0092, each containing 400 mg cimetidine. 60 (4 calendar strips of 15 tablets), £18.69. **Uses** Duodenal and benign gastric ulceration, including that associated with NSAIDs. Other conditions where reduction of gastric acid by 'Tagamet' is beneficial: persistent dyspeptic symptoms, particularly meal-related, including such symptoms associated with NSAIDs. **Dosage and administration** *For full dosage instructions see Data Sheet. Adults:* Duodenal or benign gastric ulceration, 800 mg once a day at bedtime. Otherwise usually 400 mg b.d. with breakfast and at bedtime. If inadequate, 400 mg q.d.s. with meals and at bedtime (1.6 g/day). Treat for at least 4 weeks (6 weeks in benign gastric ulcer, 8 weeks in ulcer associated with continued NSAIDs). To prevent relapse of peptic ulcer, usually 400 mg at bedtime or else 400 mg morning and at bedtime. **Children:** Over 1 year: 25-30 mg/kg/day, divided. **Contra-indication** Hypersensitivity to cimetidine. **Precautions** Impaired renal function: reduce dosage (see Data Sheet). Potentiation of oral anticoagulants, phenytoin and theophylline (see Data Sheet). Prolonged treatment: observe patients regularly. Potential delay in diagnosis of gastric cancer (see Data Sheet). Regularly observe patients with a history of peptic ulcer and on NSAIDs, especially if elderly. Care in patients with compromised bone marrow (see Data Sheet). Avoid during pregnancy and lactation. **Adverse reactions** Diarrhoea, dizziness, rash, tiredness. Gynaecomastia, occasional reversible liver damage, confusional states (usually in the elderly or very ill). Very rarely interstitial nephritis, acute pancreatitis, thrombocytopenia, agranulocytosis, headache, myalgia, arthralgia, sinus bradycardia, tachycardia, heart block, aplastic anaemia; very rare reports of alopecia, reversible impotence but no causal relationship established at usual therapeutic doses. **Legal category** POM. 7.3.89. Smith Kline & French Laboratories Limited Welwyn Garden City, Hertfordshire AL7 1EY © 1989 Smith Kline & French Laboratories Limited 'Tagamet', 'Tiltab' and the appearance of the tablets are trade marks.

SK&F
TG:AD1269



**The others
may be as
effective***

**But they
cost up to
63% more†**

TAGAMET
GIMETIDINE 800